Rheumatoid arthritis (RA) synovial fibroblasts hyperexpress the mesenchymal cadherin-11, which is involved also in tumor invasion/metastasis, whereas anti-cadherin-11 therapeutics prevent and reduce experimental arthritis. To test the hypothesis that cadherin-11 is aberrantly expressed in RA peripheral blood, 100 patients (15 studied serially) and 70 healthy controls were analyzed by real-time reverse transcription-PCR. Cadherin-11 mRNA transcripts were detected in 69.2% of moderately/severely active RA, versus 31.8% of remaining patients (p=0.001), versus 17.1% of controls (p<0.0001). Notably, cadherin-11 positivity correlated significantly and independently only with established (>1year) polyarthritis (>4 swollen tender joints), by multivariate logistic regression analysis including various possible clinical/laboratory factors. Rare cells of undefined nature, detected by flow cytometry following CD45(-) enrichment, strongly expressed surface cadherin-11 (estimated 10-50cells/ml of blood) in 5/6 patients with polyarticular established disease versus 1/6 patients with early RA. Studies on the potential pathogenic role of circulating cells expressing cadherin-11 in RA are warranted.
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease, which affects a wide variety of organs including the spleen. Splenic involvement in SLE includes conditions such as splenomegaly, hyposplenism, infarction, and spontaneous rupture. However, only a few cases of splenic calcifications in patients with SLE have been reported. Herein, we present a case of a 24-year-old female diagnosed with SLE, in which we found diffuse splenic calcifications. The unique pattern of splenic calcifications in SLE contributes to the differential diagnosis from other conditions such as infections and other connective tissue diseases, which also cause calcifications in the spleen.
Background In immunodeficient mice the subcutaneous implantation of synovial fibroblasts (SFs) derived from patients with rheumatoid arthritis (RASFs) revealed an active movement via the vasculature to the naive cartilage that led to damage, thus supporting the idea that RASFs may facilitate and drive the progression from oligo- to polyarticular disease in RA (Nat Med. 2009;15:1414). On the other hand, RASFs hyper-express cadherin-11 and anti-cadherin-11 therapy may have potential as a novel RA therapy. This adhesion molecule, which is required for synovial lining formation, is involved in tumor invasion and metastasis, and signal transduction. Objectives By considering that cadherin-11 can serve as a marker of possibly circulating RASFs and since it is not thought to be expressed in hematopoietic tissues, we tested the hypothesis that cadherin-11 gene is aberrantly expressed in the peripheral blood of RA patients with active inflammation in multiple joints. Methods Total RNA extracted from 3 ml peripheral blood samples from 70 consecutive patients with RA, 56 healthy blood donors and 47 other joint disease-control patients was subjected to quantitative real time RT-PCR for analysis of cadherin-11 gene expression. Flow-cytometry was also performed in selected RA blood samples. Inflammatory synovial fluid samples served as positive controls. Results Cadherin-11 mRNA transcripts were found in all 5 synovial fluid samples examined, as well as in the peripheral blood of 71% of those patients with active, established RA, versus 14% of healthy blood donors (p<0.0001) and 14% of those RA patients in remission. Among patients with active, established RA, cadherin-11 was expressed in 24/30 and 10/21 patients with poly- and oligoarthritis, respectively (80% versus 48%, p:0.016). The positive correlation between cadherin-11 expression and the extent of joint inflammation was confirmed in 75 % of serial samples obtained from RA patients at different disease activity phases. Cadherin-11 gene expression was not associated with ESR or CRP levels, autoantibodies, or treatment modalities. Comparable to RA results were also obtained from patients with or without active, chronic joint inflammation in the context of other connective tissue diseases (SLE/Sjogren’s/SSc, n=20) or spondylarthropathies (n=16). In contrast, cadherin-11 was not expressed in blood samples derived from 9 of 11 patients with infectious or crystal arthropathies, or osteoarthritis. By flow cytometry, cells co-expressing surface cadherin-11 and CD90(Thy-1)/CD106(VCAM-1), probably representing RASFs, were found in all synovial fluids examined. Such rare circulating cells, either or not expressing the pan-haematolymphoid marker CD45, were also identified in the peripheral blood of patients with active RA. Conclusions Cadherin-11 mRNA transcripts are frequently found in the peripheral blood of RA patients with active disease and may serve as biomarker of (auto)immune-mediated joint inflammation. These results will have important prognostic and therapeutic ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.